FindTrial
Sign In

1:1

6 trials

Sponsors

Ningxia Medical University, Xiangya Boai Rehabilitation Hospital, Shanghai Chest Hospital, Shanghai Jiaotong University, Lanzhou University Second Hospital, Institute of Clinical Pharmacy, Central South University

Conditions

Advanced hepatocellular carcinomaPerianal AbscessesPharmacokineticsPharmacokinetics and Bioequivalence Study in HumanPharmacokinetics and Bioequivalence Study in humanThymic tumor

Phase 1

Bioequivalence of Valsartan Tablets (Fasting) in the Human Body
RecruitingChiCTR-IIR-15007392
Institute of Clinical Pharmacy, Central South UniversityPharmacokinetics and Bioequivalence Study in human
Start: 2015-11-09Updated: 2017-04-18
Bioequivalence of Pericyazine Tablets (Fasting ) in the Human Body
RecruitingChiCTR-IIR-16008062
Institute of Clinical Pharmacy, Central South UniversityPharmacokinetics
Start: 2016-03-12Updated: 2017-04-18
Bioequivalance of Abavilam Tablets (Fasting) in the Human Body: A randomized cross-over controlled trial
Active, not recruitingChiCTR1900021441
Xiangya Boai Rehabilitation HospitalPharmacokinetics and Bioequivalence Study in Human
Start: 2019-03-04Updated: 2019-03-11

Phase 4

Efficacy prediction of rivaroxaban combined with targeted therapy and immunotherapy for advanced hepatocellular carcinoma
Active, not recruitingChiCTR2000040540
Lanzhou University Second HospitalAdvanced hepatocellular carcinoma
Start: 2021-01-01Updated: 2021-03-08

Unknown Phase

Applied Research of Diluted Nitrous Oxide for postoperative analgesia effcect on dressing of perianal abscess
RecruitingChiCTR1900021081
Ningxia Medical UniversityPerianal Abscesses
Start: 2019-02-28Updated: 2019-01-28
Clinical study on lymph node dissection of thymic tumors and its effect on prognosis
Active, not recruitingChiCTR2000028816
Shanghai Chest Hospital, Shanghai Jiaotong UniversityThymic tumor
Start: 2020-01-31Updated: 2020-01-13

Related Papers

FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription
Journal for ImmunoTherapy of Cancer2024-07-0114 citations